Kamada, Chiesi Farmaceutici Terminate Inhaled Alpha-1 Antitrypsin Therapy Deal Post author:Sam Post published:November 19, 2017 Post category:BioPharma Kamada now maintains full, worldwide commercial rights to its inhaled AAT. Source: BioSpace You Might Also Like Definiens AG To Host International Symposium For Tissue Phenomics April 11, 2017 Singulex Announces CE Mark For Sgx Clarity System April 2, 2017 San Diego's Arena Soars as Phase II Hypertension Trial Data Wows July 10, 2017
